Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02083185 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT02083185 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 136 participants.
The verdict
NCT02083185, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (\<50 ng/dL).
Interventions
- DRUG Relugolix
- DRUG Leuprorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2014-03-26 |
| Est. Completion | 2017-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02083185
The ClinicalTrials.gov registry entry for NCT02083185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Relugolix is the first listed.
NCT02083185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02083185 about?
NCT02083185 is a clinical study titled "A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer". The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (\<50 ng/dL).
What is the current status of trial NCT02083185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2014-03-26. Estimated completion is 2017-02-23.
What interventions are being tested in trial NCT02083185?
The interventions under investigation include: Relugolix (DRUG), Leuprorelin (DRUG).
Who is sponsoring clinical trial NCT02083185?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.